PTEN- mutations do not cause nuclear β-catenin accumulation in endometrial carcinomas

Human Pathology

Volumn 35, Issue 10, 2004, Pages 1260-1265

  Wappenschmidt, B ^a   Wardelmann, E ^b   Gehrig, A ^c   Schondorf T ^d   Maass, N ^e   Bonatz, G ^f   Gassel, A M ^c   Pietsch, T ^b   Mallmann, P ^a   Weber, B H F ^c   Schmutzler, R K ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF APPLIED SCIENCES   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f Augusta Kranken Anstalt   (Germany)

Author keywords

catenin expression; CTNNB1; endometrial carcinoma; FIGO; ILK; integrin linked kinase; International Federation of Gynecology and Obstetrics; mutations; PCR; polymerase chain reaction; PTEN; single strand conformation polymorphism; SSCP

Indexed keywords

BETA CATENIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; CANCER CLASSIFICATION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SPACE; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; STAINING;

BETA CATENIN; CARCINOMA, ENDOMETRIOID; CELL NUCLEUS; CYTOSKELETAL PROTEINS; DNA MUTATIONAL ANALYSIS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 5444244379     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2004.06.007     Document Type: Article

References (24)

1. Matias-Guiu X., Catasus L., Bussaglia E., et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol. 32:2001;569-577
2. Koul A., Willen R., Bendahl P.O., et al. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumourigenesis. Cancer. 94:2002;2369-2379
3. Kong D., Suzuki A., Zou T.T., et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet. 17:1997;143-144
4. Fukuchi T., Sakamoto M., Tsuda H., et al. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res. 58:1998;3526-3528
5. Liaw D., Marsh D.J., Li J., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 16:1997;64-67
6. Dudek H., Datta S.R., Franke T.F., et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 275:1997;661-665
7. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol. 10:1998;262-267
8. Tamura M., Gu J., Tran H., et al. PTEN gene and integrin signaling in cancer. J Natl Cancer Inst. 91:1999;1820-1828
9. Peifer M. Beta-catenin as oncogene The smoking gun. Science. 275:1997;1752-1753
10. Morin P.J., Sparks A.B., Korinek V., et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 275:1997;1787-1790
11. Behrens J., von Kries J.P., Kuhl M., et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature. 382:1996;638-642
12. Molenaar M., van de Wetering M., Oosterwegel M., et al. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell. 86:1996;391-399
13. Persad S., Troussard A.A., McPhee T.R., et al. Tumour suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol. 153:2001;1161-1174
14. Duerr E.M., Rollbrocker B., Hayashi Y., et al. PTEN mutations in gliomas and glioneuronal tumours. Oncogene. 16:1998;2259-2264
15. Freihoff D., Kempe A., Beste B., et al. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. Br J Cancer. 79:1999;754-758
16. Koch A., Denkhaus D., Albrecht S., et al. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res. 59:1999;269-273
17. Ali I.U., Schriml L.M., Dean M. Mutational spectra of PTEN/MMAC1 gene A tumour suppressor with lipid phosphatase activity. J Natl Cancer Inst. 91:1999;1922-1932
18. Sparks A.B., Morin P.J., Vogelstein B., et al. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58:1998;1130-1134
19. Risinger J.I., Hayes A.K., Berchuck A., et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 57:1997;4736-4738
20. Mutter G.L., Lin M.C., Fitzgerald J.T., et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 92:2000;924-930
21. Saegusa M., Hashimura M., Yoshida T., et al. Beta-catenin mutations and aberrant nuclear expression during endometrial tumourigenesis. Br J Cancer. 84:2001;209-217
22. Persad S., Attwell S., Gray V., et al. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci U S A. 97:2000;3207-3212
23. Novak A., Hsu S.C., Leung-Hagestein C., et al. Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proc Natl Acad Sci U S A. 95:1998;4374-4379
24. Suzuki H., Freije D., Nusskern D.R., et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 58:1998;204-209